Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment

Core Insights - Daré Bioscience has secured a contract with the Gates Foundation to receive up to approximately $300,000 for conducting a strategic landscape review related to contraceptive product development [1][2][3] - The initiative aims to identify and assess organizations with capabilities in formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support for contraceptive products [2][3] - The CEO of Daré Bioscience emphasized the importance of this funding in strengthening the global contraceptive innovation ecosystem and accelerating the translation of new contraceptive concepts into impactful products [3] Company Overview - Daré Bioscience is a health biotech company focused on addressing gaps in women's health through advanced science and real-world solutions [1][4] - The company is dedicated to developing credible, science-based solutions that meet high clinical standards, including randomized controlled trials and Good Manufacturing Practice (cGMP) requirements [5][4] - Daré's mission encompasses a wide range of women's health issues, including contraception, menopause, pelvic pain, fertility, vaginal health, and infectious diseases [4][5] Industry Context - There is a growing awareness and conversation around women's health issues, including menopause and sexual health, yet access to evidence-based solutions remains limited [5] - The funding from the Gates Foundation is part of a broader effort to enhance the contraceptive innovation ecosystem and improve women's health outcomes globally [3][5]